Emokpae Imina, Tobia Deanna L, Stamm Saskia D, Lundy Petra, Weimer Derek S, Demory Beckler Michelle
Medical School, Nova Southeastern University Dr. Kiran C. Patel College of Allopathic Medicine, Fort Lauderdale, USA.
Biomedical Sciences, Nova Southeastern University Dr. Kiran C. Patel College of Allopathic Medicine, Fort Lauderdale, USA.
Cureus. 2024 Jul 18;16(7):e64833. doi: 10.7759/cureus.64833. eCollection 2024 Jul.
Probiotics have garnered increasing attention, particularly within the realm of atopic dermatitis (AD). Although classified as dietary supplements by the Food and Drug Administration, probiotics are being explored for their potential to modify immune system responses and aid in disease recovery. This review aims to provide a current understanding of probiotics, specifically various lactobacilli strains, as a therapeutic option in preventing and treating AD. The concept of the gut-skin axis has gained substantial recognition, emphasizing the complex relationship between the gut microbiome and skin health. Dysfunctional gut barriers and metabolites produced by gut microorganisms can exert profound influences on skin conditions, including AD. Lactobacilli species are particularly noteworthy for their resilience and stability within the gastrointestinal tract, making these bacteria ideal candidates for probiotic supplementation. Various lactobacilli strains (, , ,, ) were included in this study due to their current uses in mitigating AD symptomatology. This systemic review article aims to shed light on the potential of probiotics as a therapeutic approach for AD, highlighting their stellar safety profile and promising therapeutic efficacy. Given the compelling preliminary findings and the constraints associated with conventional treatments, probiotics, particularly lactobacilli strains, emerge as a considerable alternative or adjuvant option for individuals grappling with AD. Further exploration is imperative to establish probiotics as a promising therapeutic option, providing renewed hope for those seeking effective strategies for managing AD.
益生菌已越来越受到关注,尤其是在特应性皮炎(AD)领域。尽管美国食品药品监督管理局将益生菌归类为膳食补充剂,但人们正在探索其调节免疫系统反应和帮助疾病康复的潜力。本综述旨在提供对益生菌,特别是各种乳酸杆菌菌株作为预防和治疗AD的治疗选择的当前理解。肠-皮肤轴的概念已得到广泛认可,强调了肠道微生物群与皮肤健康之间的复杂关系。肠道屏障功能失调以及肠道微生物产生的代谢产物可对包括AD在内的皮肤状况产生深远影响。乳酸杆菌属因其在胃肠道内的恢复力和稳定性而特别值得关注,使这些细菌成为益生菌补充的理想候选者。由于目前用于减轻AD症状,本研究纳入了各种乳酸杆菌菌株(、、、)。这篇系统综述文章旨在阐明益生菌作为AD治疗方法的潜力,突出其出色的安全性和有前景的治疗效果。鉴于令人信服的初步研究结果以及与传统治疗相关的局限性,益生菌,特别是乳酸杆菌菌株,成为困扰AD患者的一种相当不错的替代或辅助选择。必须进一步探索,以将益生菌确立为一种有前景的治疗选择,为那些寻求有效管理AD策略的人带来新的希望。